Core Viewpoint - The company held its 2024 annual performance briefing on May 16, 2025, to discuss financial status, market expansion, development strategy, and corporate governance with investors [1] Group 1: Company Performance - In 2024, the company achieved an operating income of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan, representing a year-on-year growth of 14.01% [2] Group 2: Strategic Focus - The company will continue to adhere to an integrated development strategy for raw materials and formulations, focusing on high-quality development, steady progress, and operational efficiency [2][4] - The company aims to enhance its product pipeline, accelerate diversified and differentiated product development, and optimize its research-production-sales management model [2][5] Group 3: Market Expansion - The company is strengthening its presence in both domestic and international markets by optimizing marketing models and enhancing terminal development and academic promotion [4] - The overseas performance is driven by maintaining market share through key partnerships and flexible pricing strategies, as well as deepening engagement in emerging markets [2][4] Group 4: Management and Governance - The company emphasizes internal management improvements, focusing on energy conservation, efficiency enhancement, and lean management to drive cost reduction and efficiency [4] - The company is committed to protecting investor rights and has increased its cash dividend ratio to over 80% for both 2023 and 2024 profit distribution plans [2]
津药药业: 津药药业股份有限公司关于2024年度业绩说明会召开情况的公告